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on the molecular bases, patho mechanisms, 
and genotype/phenotype correlations in heri-
table skin disorders. This trend continues in 
this issue, as well as in subsequent issues of the 
Journal, with a series of articles that expand the 
molecular genetics, probe the pathomechanistic 
pathways, and explore the avenues toward 
implementation of regenerative medicine for 
these currently largely intractable disorders. 
These and related publications have raised a 
number of critical questions that must be exam-
ined in the context of research toward treatment 
and eventual cure for these diseases.
Why study rare diseases?
First, collectively, these diseases are not that 
rare. Although some of the conditions, such as 
Hutchinson–Gilford progeria (1 in 1,000,000), 
are very rare, many are much more common. 
Using EB as an example, there are as many as 
20,000 to 30,000 affected individuals in the 
United States; transposing this number to the 
global level, there may be as many as close to 
half a million people affected with the skin fra-
gility syndromes in the EB spectrum worldwide 
(the world population as of 23 July 2012 was 
7,028,161,241, and that of the United States 
was 314,009,530 (Current Population Clock, 
http://www.census.gov/main/www/popclock.
html)). Most impressively, according to Francis 
Collins, the total number of individuals affected 
by rare diseases in the United States amounts to 
~26 million people (Gaestel, 2012); assuming 
the same prevalence of diseases in the global 
population, that would amount to more than 
500 million people affected with “rare” diseases.
Second, irrespective of the population-based 
prevalence numbers, an individual affected with 
any of these disorders has 100% involvement. 
With the emphasis on individualized medi-
cine, understanding any individual’s disease is 
potentially important, with great impact on 
that patient’s quality of life. In fact, it has been 
stated—for example, in the case of EB—that each 
individual affected by the disease has the right to 
diseases are considered rare in the United States when there are fewer than 200,000 affected individuals with the 
diagnosis, according to the Orphan Drug Act 
approved by the U.S. Congress in 1983. The def-
inition of a rare disease in the European Union 
is fewer than 5 affected individuals per 10,000 
inhabitants, and in Japan a disease is rare when 
it affects fewer than 50,000 people. Collectively, 
there are close to 7,000 rare diseases. Among 
them, the genetic disorders with Mendelian 
inheritance form a particularly prominent group, 
and there are as many as 1,200 different patient-
advocacy organizations under the umbrella of 
the Genetic Alliance (Sharon Terry, president 
of Genetic Alliance, Washington, DC, personal 
communication).
Although relatively rare, many of these condi-
tions have leveraged the power of patient advo-
cacy in international settings, as exemplified by 
PXE International, the premier organization in 
support of research and patient care for pseudox-
anthoma elasticum (PXE), with subsidiaries in 71 
countries globally (Terry et al., 2007). Another 
example is the coalition of DebRA International, 
a consortium of patient-advocacy organizations 
in 40 countries, representing patients and fami-
lies with different forms of epidermolysis bullosa 
(EB). These organizations wield considerable 
power over legislative bodies internationally, 
forging the research agenda and securing their 
fair share of funding from public sources (Uitto, 
2001). For example, the National Institutes of 
Health in the United States spends ~11% of its 
$30 billion annual budget on research on rare 
diseases (Collins, 2012).
The interest in the study of rare diseases is 
readily evident from examination of the publica-
tions in mainstream biomedical journals, and the 
Journal of Investigative Dermatology is among 
them, regularly publishing breakthrough articles 
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know the precise genetic mutation causing his or her condi-
tion; in Germany, this notion is anchored in the health system, 
with all mutation analyses being paid by insurance compa-
nies (Leena Bruckner-Tuderman, personal communication).
Third, even in the absence of a specific treatment for 
affected individuals, understanding the molecular bases, 
specifically identification of the mutations, can have 
major implications for the diagnosis and management of 
these disorders. For example, in the case of EB, identifica-
tion of the mutations in a newborn with a blistering disor-
der allows confirmation of the diagnosis with prognostic 
implications. Mutation detection can also assist in genetic 
counseling regarding the risk of recurrence, particularly in 
families where there is no previous history of such disease. 
Furthermore, identification of specific mutations in this 
group of disorders has formed the basis for prenatal diagnosis 
at early stages of gestation through chorionic villus sampling, 
and the diagnosis can be made even before the pregnancy 
starts through preimplantation genetic diagnosis as part of in 
vitro fertilization procedures (Uitto, 2009).
One often unappreciated consequence of the research 
on rare heritable skin diseases is a broader understanding 
of cutaneous biology in general. Examination of the muta-
tion databases on different heritable disorders has revealed 
the presence of obvious candidate genes as well as a num-
ber of surprising ones. For example, in the case of EB, as 
many as 17 genes are now known to harbor mutations in a 
manner that clinically results in skin fragility, blistering, and 
chronic ulcers, and identification of many of these genes has 
defined their precise role in providing integrity to normal 
skin (Uitto et al., 2010b). On the other hand, identification of 
mutations in the ABCC6 gene in PXE provided novel under-
standing of the role of ABC transporters in cutaneous biology, 
particularly with respect to metabolic calcium homeosta-
sis (Uitto et al., 2010a). Thus, continued exploration of the 
molecular bases and pathomechanistic consequences of the 
mutations in various heritable skin disorders is expected to 
broaden our understanding not only of the molecular genet-
ics of skin diseases and their clinical phenotypes but also of 
cutaneous biology in general. Some recent reports published 
in JID provide new understanding of some rare skin diseases. 
One report discusses digenic inheritance in EB simplex (EBS) 
(Padalon-Brauch et al., 2012), and an examination of addi-
tional families with EBS Ogna subtype confirms the unique 
role of a specific mutation (p.R2000W) in the plectin gene 
(Kiritsi et al., 2012). These studies also expand our under-
standing of genotype/phenotype correlations, for example, 
that homozygous dominant missense mutations in the kera-
tin 17 gene can lead to alopecia in patients with severe 
pachyonychia congenita (PC) (Wilson et al., 2012).
What are the candidate diseases for regenerative medicine?
One might argue that with limited resources and dwindling 
research support in the face of fiscal realities in many coun-
tries, research should be prioritized, targeting only diseases 
that are likely to maximize the yield to the benefit of the 
society. Laying aside intellectual curiosity and the chal-
lenges posed by some of the heritable skin diseases, one 
could argue that an ideal disease would be one in which 
the molecular basis is well defined, the patho mechanistic 
pathways resulting from the molecular defect are well char-
acterized, and a clear understanding of the causal correla-
tion between pathology and the clinical manifestations 
exists. One such condition is recessive dystrophic EB (RDEB), 
in which well-defined mutations in the COL7A1 gene 
result in perturbations or absence of anchoring fibrils, with 
subsequent deficiency in adhesion of the epidermis to the 
underlying dermis (Uitto et al., 2010b). These observations 
correlate well with the tendency for blistering and erosions 
of the skin as a result of external trauma. This disease could 
then be considered a potential target for regenerative medi-
cine using various approaches, spanning from gene therapy 
and cell-based approaches to protein replacement (Table 1). 
It should be noted that development of appropriate model 
systems—such as transgenic mice, which often faithfully 
recapitulate the clinical, genetic, histopathologic, and ultra-
structural features of a disease—can serve as a platform for 
development of molecular therapies (Bruckner-Tuderman et 
al., 2010). An example of such a mouse model is the kera-
tin 16 null mouse, which manifests a hallmark feature of PC 
(i.e., palmoplantar keratoderma), as reported by Lessard and 
Coulombe (2012). It is clear, then, that increased understand-
ing of rare heritable skin disorders forms the basis of treat-
ment modalities that may be repurposed for treatment of 
more common skin diseases (Uitto et al., 2012).
What are the approaches in regenerative medicine for heritable 
skin diseases?
Several concepts are being developed to counteract the 
pheno typic manifestations of heritable skin diseases, and 
some have advanced to, or will soon be ready for, clinical 
table 1. Generalized approaches of regenerative 
medicine for epidermolysis bullosa at different stages 
of development
approach developmental Stage
Cell-based therapies
Fibroblast therapy for RDEB CT
Mesenchymal stem cell application CT
Bone marrow transplantation CT
Induced pluripotent stem cells PD
Gene therapy
Ex vivo keratinocyte therapy CT
Direct gene application (gene gun) PD
Genome repair, trans-splicing, 
PTC read-through
PD
Gene silencing (siRNA) PD
Protein replacement therapy
Type VII collagen (RDEB) PD
Laminin 332 (JEB) PD
Abbreviations: CT, clinical trial stage; JEB, junctional EB; PD, preclinical 
development; PTC, premature termination codon; RDEB, recessive 
dystrophic EB; siRNA, small interfering RNA.
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trials (Table 1). One facet of regenerative medicine revolves 
around cell-based therapies, with the concept that introduc-
tion of cells—whether autologous, genetically corrected, or 
from allogeneic donors—will provide the skin with proteins 
that are defective or missing in a disease, thus improving the 
clinical picture. In fact, there has been tremendous prog-
ress toward the use of cell-based therapies for EB (Uitto et 
al., 2012). One approach uses injection of allogeneic fibro-
blasts to the periphery of blisters and erosions in patients with 
RDEB, resulting in increased deposition of type VII collagen 
and advanced wound healing (Wong et al., 2008). In addition 
to skin fibroblasts, application of mesenchymal stem cells has 
been proposed to be beneficial to patients with RDEB, and, 
in fact, a preliminary study on two patients suggested signifi-
cant improvement in wound healing (Conget et al., 2010). In 
addition to application of defined cell populations to the skin, 
bone marrow transplantation (BMT) has been suggested to be 
beneficial to patients with RDEB, with preliminary proof-of-
principle studies showing significant improvement up to at 
least one year of follow-up (Wagner et al., 2010). Although 
this original study raises cautious optimism concerning the 
potential of BMT for treating blistering skin diseases, the long-
term benefits of this procedure, in the face of considerable (up 
to 25%) mortality, must be evaluated further.
Another form of cell therapy revolves around induced plu-
ripotent stem cells (iPSCs), which can be derived from the 
patient’s own cells and, after genetic correction, grafted back 
to the patient’s skin. Initial steps toward this strategy have 
already been developed for patients with RDEB (Itoh et al., 
2011; Tolar et al., 2011) and similar studies are reported for 
junctional EB (Tolar et al., 2012). Specifically, skin fibroblasts 
cultured from skin biopsies were transduced with transcrip-
tion factors that result in iPSCs, and these cells were then 
reprogrammed to keratinocytes and genetically corrected to 
express the laminin b3-chain gene that was originally defec-
tive in the skin of patients with junctional EB. These studies 
therefore attest to the potential of iPSC technology for treat-
ing different forms of EB and other epidermal blistering dis-
eases. In this context, Higgins et al. (2012) report that human 
hair follicle dermal papilla cells can be programmed into 
iPSCs. These cells would then serve as an accessible resource 
for making iPSCs for patient-specific personalized medicine.
Finally, another source of cells for regenerative medicine 
for EB is suggested by the finding that most, if not all, patients 
with junctional EB, non-Herlitz type, exhibit revertant mosa-
icism in their skin, a form of natural gene therapy manifesting 
as patches of normal skin (Pasmooij et al., 2012). Thus, skin 
biopsies from these areas would allow culture of genetically 
corrected keratinocytes or would provide material for devel-
opment of iPSCs. These cells would then provide oppor-
tunities for cell-based therapy in which the patient’s own, 
naturally corrected cells are used as a source.
Considerable progress has also been made using small 
interfering RNAs (siRNAs) for targeting mutant alleles in heri-
table skin disorders, particularly in those depicting dominant-
negative modes of action. The siRNA can be allele-specific, 
preventing expression of the mutant allele only, or it can be 
directed to both alleles of the genes, including the mutant 
and the wild-type copy, in cases where redundancy of the 
genes in the skin is providing normal physiological function. 
It should be noted that, although the siRNA approach was 
shown to be effective in the first human clinical trial treating 
a patient with PC, the issues of siRNA delivery and the tran-
sient nature of the beneficial effects have necessitated new 
directions of research toward optimizing the delivery of these 
molecules to the skin (Leachman et al., 2010). An example 
of the use of siRNA for allele-specific inhibition of mutant 
type VII collagen in dominant dystrophic EB was presented 
by Pendaries et al. (2012). Their study took advantage of the 
observation that exon 87 and adjacent intronic sequences of 
the type VII collagen gene harbor a large number of domi-
nant-negative mutations in patients with dystrophic forms of 
EB. The investigators therefore suggested that allele-specific 
RNA interference, which would elicit in-frame skipping of 
exon 87, would eliminate the mutations and result in synthe-
sis of slightly shortened, yet functionally competent, type VII 
collagen polypeptides. Careful selection of siRNA resulted in 
up to ~58% inhibition of the expression of the mutant allele, 
providing potential for amelioration of the clinical phenotype 
in patients with dominant dystrophic EB.
Future perspective
In summary, the field of regenerative medicine for heritable 
skin diseases is moving rapidly, and new technologies and 
novel strategies are being developed, many of them already 
approaching or already within the clinical arena. It is conceiv-
able, then, that with the advent of these innovations, the field 
is making significant progress toward treatment and—poten-
tially—cure of these rare, currently intractable, disorders.
Jouni Uitto
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